STUDY GOAL AND OBJECTIVES
The purpose of this study is to analyze the market for drugs of abuse (DOA) testing globally and to provide market, technology, and revenue forecasts for the period 2008 to 2014. This report also analyzes the global environment related to regulations, national level policies, and legislation in several parts of the world that affect DOA testing markets.
This BCC report provides an in-depth look at DOA testing markets, which had sales of more than $1.9 billion in 2007. Future growth prospects of this market by various sample matrices have been analyzed based on market dynamics, technology efficacies, and regulatory factors. Regional analysis of the industry in terms of current and future trends of drug abuse and testing practices in important regions has been presented in the study. The report also identifies key market players with significant market shares, analyzes current and future strategies of these companies that will have an impact in the market, and analyzes future growth trends. Key companies participating in this market are profiled.
This report also analyzes the current and possible future legislations affecting the market in the U.S. and other countries, and examines the influence of these acts in the development of the industry. Finally, several testing technologies have been discussed and testing trends with respect to various sample matrices have been presented in the report, identifying the likely trends in the foreseeable future.
REASONS FOR DOING THE STUDY
BCC published a comprehensive report on DOA testing in 2002. Since then, the DOA industry has undergone many noteworthy changes. One key factor that was instrumental in these changes is the extensive growth of narcotics markets and consequently governmental initiatives and efforts to combat and eradicate these markets, not only in favor of crimes related to the narcotics, but also to ensure quality in the social structure within the nation. This has led the regulatory framework in several countries to undergo changes and evolve over time to address drug production and trafficking.
This report analyzes the current and emerging trends in the market. In addition, it also analyzes regulatory issues for several countries related to drug trafficking and abuse that illustrate the nation’s stand on narcotics and its awareness among the masses that potentially affects DOA testing sales within these markets.
This study offers insight into the successful strategies adopted by companies that helped them improve their market shares in the DOA testing markets. High-growth markets in terms of geographic regional growth trends for various sample matrices for drug of abuse testing are identified. Strategies adopted by big in vitro diagnostic companies as well as small innovative diagnostic companies entering the market have been identified. These detailed analyses are targeted to assist developers and decision makers of healthcare diagnostics companies. The report includes detailed analyses of the regulatory factors that have been instrumental in driving the industry in developed countries. This is especially suitable for legislators involved in government policy development programs. Technology trend analysis gives an overview of successful technologies, which is helpful for research managers in charge of project identification and development.
SCOPE OF REPORT
This report contains:
- An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
- Drug abuse statistics in key regions.
- Analysis of regulatory environments in North, South and Central America, Europe, and Asia Pacific, and country-wise summaries of national legislation and policies.
- Drug of abuse testing markets with respect to testing approaches and sample matrices.
- Technology trends in the drug of abuse testing market.
- Leading players in the market and their key products.
- Sales projections through 2014 for drug of abuse testing markets by sample matrix and geographic regions.
- Analysis of leading companies and their successful strategies.
The base year of this study is 2007. Market figures are based on the revenues at the manufacturer’s level and are projected at 2007 dollar value (i.e., inflation is not computed into the projection figures). Forecasts are mainly based on the projections of the marketers. Growth of competing products, technologies, drug of abuse growth trends, government policies, and trends in the in vitro diagnostics (IVD) market have also been considered for estimating the future growth trends.
Data to prepare this study was derived from regulatory agencies, trade literature, patient support groups, and annual reports of companies and industry related databases. In addition, discussion with product managers of diagnostic companies, research executives, academic researchers, and government agency spokespersons have been conducted for gaining insights about the market, strategies, and future trends.
The information and analysis presented in this report are based on an extensive survey of the DOA industry as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, trade associations, and national and world health organizations. Key information from the literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.
Syamala Ariyanchira was involved in chemical and pharmaceutical research for 7 years before moving into industry analysis. For the past 5 years, she has been actively involved in chemical and healthcare industry analysis. She has a PhD in chemistry and post-doctoral experience in biophysics.